The Napp Immunology Academy aims to provide high quality training and non-promotional educational resources to healthcare professionals, to support them in delivering the best possible care to their patients, particularly in relation to the development and use of biosimilar medicines.
In this section you will find non-promotional educational webinars with a practical emphasis, to empower you to support your patients and maintain your own psychological wellbeing.
Dr Barry Quinn, who is a senior lecturer in Oncology at Queens University Belfast and has worked in the field of oncology and palliative care for over 30 years as a clinical educator, discusses different leadership styles in this webinar. He also offers practical approaches to empower nurses to support their patients and lead their colleagues around the changing NHS & NICE guidelines for cancer patients during COVID-19.
Dr Alison Pearce, Lead Consultant Psychologist, University Hospital Southampton & Southern Health Foundation Trust, and Daniel Winter-Bates, Programme Lead for Wellbeing during COVID-19, University Hospital Southampton discuss ways in which healthcare professionals can identify the signs and symptoms of stress, and identify practical coping strategies to maintain psychological wellbeing during the pandemic and beyond.
This section offers an overview of cancer cell biology, an introduction to antibody-based treatments, and future developments.
In this non-promotional webinar, Dr Elaine Vickers, founder of Science Communicated, an independent education provider specialising in cancer biology and the science behind targeted cancer treatments provides an overview of cancer cell biology, and the structure, types and mechanisms of action of antibody-based treatments.
Dr Elaine Vickers, founder of Science Communicated, discusses the background to the development of antibody-based cancer treatments and explains how scientists are now improving these agents by adding a chemotherapy payload, or creating custom-made proteins with entirely new properties, with chimeric antigen receptor (CAR)-T cell therapies showing particular promise especially in haematological cancers.
This non-promotional animation provides
UK/INM-20016
Date of preparation: September 2020